Effect of Glycemic Regulation on Endocan Levels in Patients with Diabetes

Angiology

Volumn 67, Issue 3, 2016, Pages 239-244

  Arman, Yucel ^a   Akpinar, Timur Selcuk ^b   Kose, Murat ^b   Emet, Samim ^b   Yuruyen, Gulden ^a   Akarsu, Murat ^a   Ozcan, Mustafa ^a   Yegit, Ozan ^b   Cakmak, Ramazan ^b   Altun, Ozgur ^a   Aydin, Sengul ^a   Alibeyoʇlu, Alpay ^b   Ugurlu, Bilal ^a   Akcan, Tugce ^b   Tukek, Tufan ^b  

^a OKMEYDANI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

endocan; fasting blood glucose; microalbuminuria; type 2 diabetes

Indexed keywords

ALBUMIN; CREATININE; DELTA ENDOTHELIAL SPECIFIC MOLECULE 1; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIAL SPECIFIC MOLECULE 1; GLUCAGON; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PROTEOGLYCAN; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; ESM1 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; ALBUMINURIA; BLOOD; COMPLICATION; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIET; DOWN REGULATION; DRUG EFFECTS; EXERCISE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK REDUCTION; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ALBUMINURIA; BIOMARKERS; BLOOD GLUCOSE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIET; DOWN-REGULATION; EXERCISE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; ODDS RATIO; PROSPECTIVE STUDIES; PROTEOGLYCANS; RISK REDUCTION BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84958693402     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319715585664     Document Type: Article

References (26)

1. Alberti KG, Zimmet PZ,. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;(15): 539-553.
2. Menon P, Kocher ON, Aird WC,. Endothelial cell specific molecule-1 (ESM-1), a novel secreted proteoglycan stimulates vascular smooth muscle cell proliferation and migration. Circulation. 2011; 124 (21): A15455.
3. Zhang SM, Zuo L, Zhou Q, et al. Expression and distribution of endocan in human tissues. Biotech Histochem. 2012; 87 (3): 172-178.
4. Afsar B, Takir M, Kostek O, Covic A, Kanbay M,. Endocan: a new molecule playing a role in the development of hypertension and chronic kidney disease? J Clin Hypertens (Greenwich). 2014; 16 (12): 914-916.
5. Bechard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001; 167 (6): 3099-3106.
6. Yilmaz MI, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014; 86 (6): 1213-1220.
7. Balta S, Mikhailidis DP, Demirkol S, et al. Endocan-a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014; 65 (9): 773-777.
8. Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behcet disease. J Am Acad Dermatol. 2014; 70 (2): 291-296.
9. Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013; 169 (5): 1066-1070.
10. Oltean S, Pullerits R, Floden A, Olausson M, Oltean M,. Increased resistin in brain dead organ donors is associated with delayed graft function after kidney transplantation. J Transl Med. 2013; 11: 233.
11. Li S, Wang L, Wang C, et al. Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantation. Urology. 2012; 80 (3): 738. e731-e738.
12. Kose M, Emet S, Akpinar TS, et al. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology. 2014. doi: 10.1177/0003319714548870.
13. American Diabetes A,. Standards of medical care in diabetes-2014. Diabetes Care. 2014; 37 (suppl 1): S14-S80.
14. Anderson JW, Kendall CW, Jenkins DJ,. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr. 2003; 22 (5): 331-339.
15. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35 (6): 1364-1379.
16. Mullan RJ, Montori VM, Shah ND, et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med. 2009; 169 (17): 1560-1568.
17. Basevi V, Di Mario S, Morciano C, Nonino F, Magrini N,. Comment on: American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34(suppl 1):S11-S61. Diabetes Care. 2011; 34 (5): e53; author reply e54.
18. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH,. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002; 51 (4): 1157-1165.
19. Wang XS, Yang W, Luo T, Wang JM, Jing YY,. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genet Test Mol Biomarkers. 2015; 19 (3): 124-127.
20. Lee W, Ku SK, Kim SW, Bae JS,. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014; 229 (5): 620-630.
21. Su YH, Shu KH, Hu CP, et al. Serum endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transplant Proc. 2014; 46 (2): 323-327.
22. Celik T, Balta S, Karaman M, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015; 24 (1): 55-60.
23. Tadzic R, Mihalj M, Vcev A, et al. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res. 2013; 37 (2-3): 103-115.
24. Dandona P, Aljada A, Bandyopadhyay A,. The potential therapeutic role of insulin in acute myocardial infarction in patients admitted to intensive care and in those with unspecified hyperglycemia. Diabetes Care. 2003; 26 (2): 516-519.
25. Meigs JB, Ralph B, D'Agostino S, Nathan DM, et al. Framingham Offspring Study. Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care. 2002; 25 (6): 977-983.
26. Caballero AE, Delgado A, Aguilar-Salinas CA, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2004; 89 (8): 3943-3948.